A COMPREHENSIVE SAFETY ANALYSIS OF 6026 PATIENTS FROM PHASE 2 AND 3 SHORT AND LONG TERM CLINICAL TRIALS WITH EVOLOCUMAB (AMG 145)

Over the last 3 years, SC administered evolocumab, a fully human monoclonal antibody to PCSK9, has been shown to robustly reduce LDL-C and be well tolerated. We now report the pooled safety analysis with evolocumab in patients participating in phase 2 or 3 randomized and placebo/comparator-